Cephapirin
An early first-generation parenteral cephalosporin antibiotic that was used for the treatment of infections caused by susceptible gram-positive organisms, including surgical prophylaxis. It has a short duration of action compared to some newer cephalosporins. It is largely obsolete in human medicine but continues to have use in veterinary practice.
Molecular Weight
423.5000 g/mol
LogP
-1.10
TPSA
177.00 Ų
Lipinski RO5
Pass
Mechanism of Action
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
2D Structure
Cite this structure
Embed this structure
SMILES
CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CSc3ccncc3)[C@H]2SC1
InChI
InChI=1S/C17H17N3O6S2/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11/h2-5,13,16H,6-8H2,1H3,(H,19,22)(H,24,25)/t13-,16-/m1/s1
Molecular Formula
C17H17N3O6S2
HBD / HBA
2 / 9
Rotatable Bonds
8
Heavy Atoms
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
An early first-generation parenteral cephalosporin antibiotic that was used for the treatment of infections caused by susceptible gram-positive organisms, including surgical prophylaxis. It has a short duration of action compared to some newer cephalosporins. It is largely obsolete in human medicine but continues to have use in veterinary practice.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Cephapirin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1599. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 30699. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cephapirin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cephapirin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cephapirin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cephapirin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cephapirin"></drugfyi-drug>